Skip to main content
Fig. 3 | Pediatric Rheumatology

Fig. 3

From: Intravenous dosing of tocilizumab in patients younger than two years of age with systemic juvenile idiopathic arthritis: results from an open-label phase 1 clinical trial

Fig. 3

Mean observed serum concentrations at baseline and week 12 in patients younger than 2 years of age and in patients 2 to 17 years of age for a sIL-6R, b CRP, and c ESR. Data are mean ± SD. Patients younger than 2 years (n = 11); patients weighing < 30 kg and receiving TCZ 12 mg/kg IV Q2W were included from the study in patients 2 to 17 years of age (n = 38). ESR: upper limit of normal, 20 mm/h; CRP: upper limit of normal, generally considered to be 0–4.9 mg/L in adults. CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; IV, intravenous; Q2W: every 2 weeks; sIL-6R: soluble interleukin-6 receptor; SD: standard deviation; TCZ: tocilizumab; Tx: treatment; y: year

Back to article page

Pediatric Rheumatology

ISSN: 1546-0096